Sun Acquisitions

AUGUST 5, 2024

These shell companies are formed for the sole purpose of raising capital through an initial public offering (IPO) to acquire an existing business within a specified timeframe. In conclusion, the M&A landscape is evolving rapidly, driven by emerging trends and shifting market dynamics.

M&A 59

M&A Mergers and Acquisitions IPO Valuation 59

Cooley M&A

JANUARY 30, 2024

As we look ahead to the 2024 proxy season (and beyond), let’s review the key 2023 trends and developments from activism playbooks, with a sharp focus on the ever-changing landscape in the technology and healthcare sectors. 10] So, what does place tech and healthcare companies in activist crosshairs? Momentum building for 2024?

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 23, 2024

Reverse mergers remain a fixture 2023 opened the door for reverse merger transactions to underperforming small and midsized public life sciences companies that were trading below their initial public offering price and, often, below the value of their cash on hand. billion.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. 2022 was the busiest year for activism in the past four years, and the healthcare and life sciences industry was no exception.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. billion acquisition of Catalent, a leader in contract manufacturing for cell and gene therapies, stands out as the largest healthcare deal of 2024.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64